In the Western population, hepatitis C, alcoholic cirrhosis, and non-alcoholic steatohepatitis (NASH) are the main underlying causes.

Unfortunately, these tumors can often be radioresistant and surgical removal of the entire tumor may not be possible. Glioblastoma (GBM) is a highly complex disease with little effective treatment options. New Immunotherapy drugs provide an alternate approach to treatment, aiming to bolster the immune system to eradicate disease.

Immunotherapy drugs provide an alternate approach to treatment, aiming to bolster the immune system to eradicate disease. In the past, use of antibody therapies has been limited in GBM due to the obstruction caused by the blood brain barrier to therapy delivery.

One of the most commonly utilized syngeneic mouse models of mammary cancer is 4T1. We have characterized our 4T1-luc2 model to support studies with novel immuno-oncology agents.

Adoptive cell therapy (ACT) with T-cells reprogrammed to express chimeric antigen receptors (CAR T-cells) bind specific antigens on the surface of cancer cells and trigger a cytotoxic response.

Advancements in Using Immuno-oncology Combination Therapies for Breast Cancer

While several treatment options are available to fight hormone- or Her2-driven breast cancers, options are somewhat limited for 

The EMT6 model was derived from a transplanted hyperplastic alveolar metastatic lung nodule in BALB/c mice.⁴   As further data was generated with this model, observations of metastatic foci in the lung visible upon gross necropsy occurred in up to 40% of control mice.  As metastasis is common in

Glioblastoma (GBM) patients are known to have a poor prognosis and tumor progression with high mortality and a median survival of only 12-15 months. Currently, anti-GBM therapy includes a multi-modality method involving radiotherapies and surgical removal of the tumor in combination with chemotherapy.¹

An estimated one in 20 people will develop colon cancer, making it one of the most frequently diagnosed cancers both in men and women. Due to improved screening methods, the overall incidence of colon cancer has declined during the past 20 years.

In this spotlight, we present data from our initial growth and efficacy studies with the E0771 model. The data presented here provides an overview of the E0771 cell line?s response to immuno-oncology agents and radiation therapy to enable design of rational combination studies.